Edu Butyrose
  • Responsabile scientifico
  • Articoli
    • BARRIERA EPITELIALE INTESTINALE
    • BUTIRRATO
    • COVID-19
    • GVHD – Graft-versus-Host Disease / Malattia del trapianto contro l’ospite
    • IBS
    • IBD
    • IDROSADENITE SUPPURATIVA
    • LINEE GUIDA
    • MALATTIE METABOLICHE
    • MALATTIA DIVERTICOLARE
    • RADIOTERAPIA
    • RIGENERAZIONE CUTANEA
  • Interviste
  • Eventi
  • Studi in corso
  • Riviste
  • Documenti utili
  • LSC
  • SILA
  • Logout
Seleziona una pagina
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study targeting gut microbiota

Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study targeting gut microbiota

da admin | Dic 23, 2025 | LETTERATURA BUTYROSE

Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study targeting gut microbiota Sonia Facchin, Matteo Calgaro, Mattia Pandolfo, Andrea Buda, Brigida Barberio, Fabiana Zingone, Nicola Vitulo, Edoardo Vincenzo...
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study targeting gut microbiota

The Protective Role of Butyrate against Obesity and

da admin | Mar 20, 2024 | MALATTIE METABOLICHE

Non hai il permesso di visualizzare questo contenuto.
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study targeting gut microbiota

Gut microbiome and health: mechanistic insights

da admin | Mar 20, 2024 | MALATTIE METABOLICHE

Non hai il permesso di visualizzare questo contenuto.
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study targeting gut microbiota

Microbiota-derived butyrate dynamically regulates intestinal homeostasis through regulation of actin-associated protein synaptopodin

da admin | Ago 2, 2023 | BARRIERA EPITELIALE INTESTINALE

Non hai il permesso di visualizzare questo contenuto.
Impact of oral butyrate on clinical and biochemical parameters in IBD: A randomized placebo-controlled study targeting gut microbiota

Microbial-derived Butyrate Promotes Epithelial Barrier Function Through IL-10 Receptor-dependent Repression of Claudin-2

da admin | Ago 2, 2023 | BARRIERA EPITELIALE INTESTINALE

Non hai il permesso di visualizzare questo contenuto.
« Post precedenti

Articoli recenti

  • Global guidelines on diverticular disease of the colon: the Fiesole Consensus report
  • Gut microbiota in symptomatic uncomplicated diverticular disease stratifies by severity of abdominal pain
  • Micro-encapsulated and colonic-release sodium butyrate modulates gut microbiota and improves abdominal pain in patients with symptomatic uncomplicated diverticular disease
  • Microencapsulated sodium butyrate administered to patients with diverticulosis decreases incidence of diverticulitis—a prospective randomized study
  • Rifaximin in diverticulosis and diverticular disease: a national survey among Italian gastroenterologists and general practitioners

Commenti recenti

    ideA-Z Project in progress S.r.l. | P.IVA: IT03373190960
    Corso Giacomo Matteotti, 48 – 20081 – Abbiategrasso (MI) | info@idea-z.it